Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma

Cristina Meazza, Michela Casanova, Roberto Luksch, Marta Podda, Francesca Favini, Graziella Cefalo, Maura Massimino, Andrea Ferrari

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate. Prolonged continuous infusion seems an attractive administration modality. Methods: Ifosfamide 14 g/m 2 (with mesna 14 g/m 2) was administered through an ambulatory portable pump over 14 days as a continuous infusion, starting every 3 weeks, in 14 patients with relapsing sarcomas. No growth factors were given. Results: Acute grade 3 hematological toxicity was observed in only 13/66 cycles and red cell transfusions were given in two patients. Hematuria and dysuria occurred in three cases. The response rate was: five partial responses, five stable disease. The median time to progression was 3 months (range: 2-19 months). The best response rate was seen for synovial sarcoma and Ewing sarcoma. Conclusion: Prolonged 14-day continuous infusion of high-dose ifosfamide is well tolerated. Potentially interesting preliminary responses in pediatric patients already treated with ifosfamide are reported. Pediatr Blood Cancer.

Original languageEnglish
Pages (from-to)617-620
Number of pages4
JournalPediatric Blood and Cancer
Volume55
Issue number4
DOIs
Publication statusPublished - Oct 2010

Keywords

  • Bone sarcomas
  • Chemotherapy
  • Continuous infusion
  • High-dose
  • Ifosfamide
  • Pediatric sarcomas
  • Relapsing sarcomas
  • Soft tissue sarcomas

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Fingerprint Dive into the research topics of 'Prolonged 14-day continuous infusion of high-dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma'. Together they form a unique fingerprint.

Cite this